Extended Data Fig. 1: Patient disposition for the DLBCL cohort. | Nature Cancer

Extended Data Fig. 1: Patient disposition for the DLBCL cohort.

From: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

Extended Data Fig. 1

N = 127 patients enrolled into the DLBCL cohort and evaluated for efficacy and safety. n numbers represent the number of patients who received the 1/20 mg or 0.7/4/20 mg cycle 1 step-up dosing regimens, those who discontinued treatment (and reasoning), and those with ongoing treatment at the time of data cut-off (August 18, 2023). DLBCL, diffuse large B-cell lymphoma.

Source data

Back to article page